Beck, Lisa A.

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 2,110

Atopic dermatitis

Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 1,549

Cytokine modulation of atopic dermatitis filaggrin skin expression

Howell, M. D., Kim, B. E., Gao, P., Grant, A. V., Boguniewicz, M., DeBenedetto, A., Schneider, L., Beck, L. A., Barnes, K. C., & Leung, D. Y. M. (2007) · Journal of Allergy and Clinical Immunology

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 1,084

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials

Simpson, E. L., Lacour, J. ‐., Spelman, L., Galimberti, R., Eichenfield, L. F., Bissonnette, R., King, B. A., Thyssen, J. P., Silverberg, J. I., Bieber, T., et al. (2020) · British Journal of Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 396

Chemokines: key players in innate and adaptive immunity

Esche, C., Stellato, C., & Beck, L. A. (2005) · Journal of Investigative Dermatology

Chemokine receptors and signalingImmune Response and Inflammation

Cited by 385

Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Deleuran, M., Thaçi, D., Beck, L. A., de Bruin-Weller, M., Blauvelt, A., Forman, S., Bissonnette, R., Reich, K., Soong, W., Hussain, I., et al. (2020) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesPsoriasis: Treatment and Pathogenesis

Cited by 255

Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial

Beck, L. A., Bieber, T., Weidinger, S., Tauber, M., Saeki, H., Irvine, A. D., Eichenfield, L. F., Werfel, T., Arlert, P., Jiang, L., et al. (2023) · Journal of the American Academy of Dermatology

Dermatology and Skin DiseasesContact Dermatitis and Allergies

Cited by 56

Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum

Bin, L., Malley, C., Taylor, P., Preethi Boorgula, M., Chavan, S., Daya, M., Mathias, M., Shankar, G., Rafaels, N., Vergara, C., et al. (2021) · Allergy

Dermatology and Skin DiseasesHerpesvirus Infections and Treatments

Cited by 33

Replicated methylation changes associated with eczema herpeticum and allergic response

Boorgula, M. P., Taub, M. A., Rafaels, N., Daya, M., Campbell, M., Chavan, S., Shetty, A., Cheadle, C., Barkataki, S., Fan, J., et al. (2019) · Clinical Epigenetics

Epigenetics and DNA MethylationDermatology and Skin Diseases

Cited by 28

Dangerous Allergens: Why Some Allergens are Bad Actors

Georas, S. N., Rezaee, F., Lerner, L., & Beck, L. (2010) · Current Allergy and Asthma Reports

Asthma and respiratory diseasesAllergic Rhinitis and Sensitization

Cited by 16